IPM Take
For decades, diabetes treatment has largely focused on glucose. More recently, weight management became the dominant story. Now a different question is emerging: what if some patients are being driven by excess cortisol? The significance of CAPTAIN-T2D is not simply the drug being tested. It is the idea that type 2 diabetes may contain biologically distinct subgroups that can be identified and treated differently. Oncology has already moved in this direction. Diabetes may be starting to follow.
Executive Summary
Sparrow Pharmaceuticals has launched the Phase 2b CAPTAIN-T2D trial evaluating clofutriben, an investigational oral 11β-HSD1 inhibitor designed to reduce intracellular cortisol production in patients with difficult-to-control type 2 diabetes and elevated cortisol. The study will screen patients using a simple overnight dexamethasone suppression test before randomisation. Researchers hope the approach will identify a subgroup of patients whose metabolic dysfunction is partly driven by excess cortisol activity. While the concept remains early-stage, it reflects growing interest in applying precision medicine principles to common chronic diseases such as diabetes.
Why it matters
- Clinicians: May provide a future pathway for identifying patients whose diabetes remains poorly controlled despite multiple therapies.
- Researchers: Supports growing interest in biological stratification of type 2 diabetes rather than treating all patients as a single population.
- Regulators: Could introduce new questions around companion diagnostics, biomarker validation and patient selection.
- Patients: May eventually lead to more personalised treatment options for people who do not respond adequately to existing therapies
Type 2 diabetes is often discussed as if it were a single disease.
In reality, patients arrive at diabetes through different biological pathways. Some are driven primarily by obesity. Others by insulin resistance, beta-cell dysfunction, genetics or chronic inflammation.
Researchers are increasingly asking whether cortisol belongs on that list.
The CAPTAIN-T2D trial is built around that idea. Rather than testing a new therapy in all patients with type 2 diabetes, investigators are specifically searching for individuals with elevated cortisol levels who continue to struggle with glycaemic control despite multiple existing treatments.
The investigational drug, clofutriben, works by inhibiting 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), an enzyme responsible for converting inactive cortisone into active cortisol inside tissues such as the liver, adipose tissue and pancreas.
The concept itself is not new. Researchers have explored 11β-HSD1 inhibition for more than a decade as a potential strategy for addressing insulin resistance, hyperglycaemia and broader metabolic dysfunction. Earlier studies demonstrated improvements in HbA1c, fasting glucose and cardiometabolic markers, although no therapy has yet successfully reached late-stage clinical adoption.
What is new is the precision approach.
Instead of assuming all patients might benefit, CAPTAIN-T2D uses biomarker screening to identify those most likely to have cortisol-driven disease biology. Participants are first screened using an overnight dexamethasone suppression test before entering the treatment phase.
That shift mirrors a broader trend already familiar in oncology, where molecular testing increasingly determines which patients receive specific therapies.
The implications extend beyond diabetes.
If successful, the study could support a future model where metabolic diseases are subdivided according to biological drivers rather than managed as broad diagnostic categories. Such an approach could influence treatment selection, clinical pathways and even reimbursement decisions.
The trial remains early-stage and many questions remain unanswered. Researchers still need to demonstrate that identifying elevated cortisol translates into meaningful clinical benefit, improved outcomes and an acceptable safety profile.
But the signal is worth watching.
For IPM, the bigger story is not cortisol itself. It is the possibility that one of the world’s most common chronic diseases may be entering the era of precision medicine.
